Drug profile · INN
dronabinol
MARINOL
dronabinol (MARINOL) is a cannabinoid cb1 receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — dronabinol
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 16
- Data quality
- 0.84
Quick answer
dronabinol (MARINOL) is a cannabinoid cb1 receptor agonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cannabinoid CB1 receptor agonist
Primary target: Cannabinoid receptor 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is dronabinol?
dronabinol (MARINOL) is a cannabinoid cb1 receptor agonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dronabinol?
MARINOL is a marketed brand name for dronabinol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dronabinol?
dronabinol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.